The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
CMOs showed an increasing reluctance to take on debt in 2022
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
This product will be launched through Granules Consumer Health (GCH) division
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Subscribe To Our Newsletter & Stay Updated
